Skip to main content
CING
NASDAQ Life Sciences

Cingulate Posts Q3 Loss, $23.2M Cash, Targets Dec 2026-Jan 2027 NDA Resubmission

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$4.25
Mkt Cap
$62.53M
52W Low
$3.16
52W High
$11.89
52W Position info
34% above low
Off High info
64% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

CING sits 34% above its 52-week low of $3.16.

Summary

Cingulate reported a $7.7 million Q3 2026 net loss and $23.2 million in cash it says funds operations into mid-2027, while expecting to resubmit the CTx-1301 NDA between December 2026 and January 2027 after substantially completing the FDA's requested manufacturing work.


Key Events · Earnings and Guidance · CING

  • Q3 2026 Results and Cash Position

    Cash and cash equivalents stood at $23.2 million at September 30, 2026, versus $11.0 million at December 31, 2025; net loss was $7.7 million for the quarter and $22.9 million for the nine months.

  • Runway Into Mid-2027

    Management believes cash funds operations into mid-2027, including CTx-1301 regulatory costs, after $20.4 million of operating cash use in the first nine months and $22.5 million raised on the ATM and Lincoln Park purchase agreement.

  • NDA Resubmission Targeted Dec 2026-Jan 2027

    Manufacturing work addressing the FDA's CMC information requests is substantially completed; the resubmission is expected to be classified Class 1 or Class 2, with two- and six-month review goals respectively.

  • SG&A Nearly Doubles Year-to-Date

    SG&A rose 45.5% to $4.6 million in Q3 and 116.6% to $14.2 million for the nine months on commercial readiness build-out through Indegene, ahead of any approval.


Analysis · CING · Life Sciences

The headline number is the cash: $23.2 million at September 30, 2026, up from $11.0 million at year-end 2025 after raising $12.0 million in a Q1 private placement and $22.5 million across the ATM and Lincoln Park purchase agreement, against $20.4 million burned on operations. Management now says that funds operations into mid-2027, which covers the expected December 2026-January 2027 resubmission of the CTx-1301 NDA and a Class 1 or Class 2 FDA review of two or six months. That runway math is the whole story for a company whose last 10-Q carried a going concern warning: the resubmission is the binary event, and the cash balance determines whether shareholders get to see the outcome without another heavily dilutive raise. The cost side is moving the wrong way — SG&A jumped 45.5% to $4.6 million in the quarter and 116.6% to $14.2 million year-to-date as Cingulate builds commercial readiness through Indegene before it has an approved product, pushing the nine-month net loss to $22.9 million from $16.2 million. Separately, the Item 1.01 amendment adds Maxim Group as a second ATM sales agent with the $100 million capacity unchanged and no shares sold, so it is an update to the March 24, 2026 program rather than new financing.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CING was trading at $4.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $62.5M. The 52-week trading range was $3.16 to $11.89. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CING - Latest Insights

CING
Nov 10, 2026, 8:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.75
Real-time Price: $4.25 info
Change: -$0.500 (-11%) info
Market Cap: $62.53M info
CING
Aug 13, 2026, 8:45 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.12
Real-time Price: $4.25 info
Change: -$0.870 (-17%) info
Market Cap: $62.53M info
CING
Aug 13, 2026, 8:40 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.12
Real-time Price: $4.25 info
Change: -$0.870 (-17%) info
Market Cap: $62.53M info
CING
Jul 02, 2026, 8:40 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.90
Real-time Price: $4.25 info
Change: -$1.65 (-28%) info
Market Cap: $62.53M info
CING
Jun 16, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.87
Real-time Price: $4.25 info
Change: -$0.616 (-13%) info
Market Cap: $62.53M info